Advanced

Long-term rivastigmine treatment in a routine clinical setting.

Minthon, Lennart LU ; Wallin, Åsa LU ; Eriksson, Sture; Wattmo, Carina LU and Andreasen, Niels (2009) In Acta Neurologica Scandinavica 119(3). p.180-185
Abstract
Objective - The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer's disease (AD) in a routine clinical setting. Methods - This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician's Interview-Based Impression of Change (CIBIC) and the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). Results - Of 217 patients initiated into rivastigmine treatment, 62% (n = 135) remained on treatment for 24 months. Most patients droped out due to nursing home placement or side effects. Eighty per cent and 67% of completers exhibited a symptomatic... (More)
Objective - The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer's disease (AD) in a routine clinical setting. Methods - This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician's Interview-Based Impression of Change (CIBIC) and the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). Results - Of 217 patients initiated into rivastigmine treatment, 62% (n = 135) remained on treatment for 24 months. Most patients droped out due to nursing home placement or side effects. Eighty per cent and 67% of completers exhibited a symptomatic attenuation of cognitive decline (</= 4-point deterioration) as assessed by using the MMSE and ADAS-cog respectively. Forty-four percent showed an unchanged/improved CIBIC rating. Conclusions - Over 60% of patients remained on treatment for 2 years in this routine clinical setting. In patients who remained on treatment, rivastigmine appeared to stabilize their condition and prevented or delayed symptomatic decline. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, rivastigmine, dementia.
in
Acta Neurologica Scandinavica
volume
119
issue
3
pages
180 - 185
publisher
Wiley-Blackwell
external identifiers
  • wos:000262949100006
  • pmid:18759798
  • scopus:59249086493
ISSN
1600-0404
DOI
10.1111/j.1600-0404.2008.01086.x
language
English
LU publication?
yes
id
de71e466-e1ac-4aa2-b9e0-fe2813aa6b17 (old id 1243623)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18759798?dopt=Abstract
date added to LUP
2008-10-03 14:02:17
date last changed
2017-01-01 05:45:13
@article{de71e466-e1ac-4aa2-b9e0-fe2813aa6b17,
  abstract     = {Objective - The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer's disease (AD) in a routine clinical setting. Methods - This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician's Interview-Based Impression of Change (CIBIC) and the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). Results - Of 217 patients initiated into rivastigmine treatment, 62% (n = 135) remained on treatment for 24 months. Most patients droped out due to nursing home placement or side effects. Eighty per cent and 67% of completers exhibited a symptomatic attenuation of cognitive decline (&lt;/= 4-point deterioration) as assessed by using the MMSE and ADAS-cog respectively. Forty-four percent showed an unchanged/improved CIBIC rating. Conclusions - Over 60% of patients remained on treatment for 2 years in this routine clinical setting. In patients who remained on treatment, rivastigmine appeared to stabilize their condition and prevented or delayed symptomatic decline.},
  author       = {Minthon, Lennart and Wallin, Åsa and Eriksson, Sture and Wattmo, Carina and Andreasen, Niels},
  issn         = {1600-0404},
  keyword      = {Alzheimer's disease,rivastigmine,dementia.},
  language     = {eng},
  number       = {3},
  pages        = {180--185},
  publisher    = {Wiley-Blackwell},
  series       = {Acta Neurologica Scandinavica},
  title        = {Long-term rivastigmine treatment in a routine clinical setting.},
  url          = {http://dx.doi.org/10.1111/j.1600-0404.2008.01086.x},
  volume       = {119},
  year         = {2009},
}